"From that amount, we will establish an indemnity fund to cover the cost of hospitalization and treatment of children who will get sick due to the dengue vaccine", Duque said.
As this disclosure was made only after the health department had already vaccinated thousands of school children, the news created a scare among parents and the public.
If reports were true that the child from Tarlac suffered from dengue 16 months since her first Dengvaxia shot and if the DOH chief was referring to the same girl, then that claim that the vaccine has a 30-month protection period would be unreliable.
The government is still determining the number of children who fell ill after the mass dengue immunization was launched in April previous year.
Sanofi Pasteur said Friday it's working with Philippine authorities to address fears and share new information about the vaccine, and will cooperate in an ongoing review of the public vaccination program.
Duque said the number of children, ages 9 and above, inoculated with Dengvaxia has risen to about 830,000 from an initial estimate of almost 734,000 after further verification by the Department of Health.
Duque said congressional hearings into the issue would start next week. Duque said the normal count is around 250,000 to 450,000.
The DOH is backing the investigation to be conducted by Congress on the dengue vaccine mess.
Sanofi Pasteur said its long-term follow-up study of the vaccine showed sustained benefits for up to six years for those who had a previous dengue infection, but that people who never had dengue had an increased risk of a severe case and hospitalization from the third year after immunization.
Last week, the Department of Health in the Philippines suspended the use of Dengvaxia produced by French drug giant Sanofi.
"I have a video of an interview of Secretary Ubial saying Dengvaxia was safe and that the adverse effects were low", Roque said.
A draft of the House Committee on Health report in 2016 said that there were 997 reported cases of individuals who experienced adverse events following immunization.
He said the former health secretary's "flip-flopping on the dengue vaccine issue" was one of the reasons why he opposed her confirmation.
He also said that there were nine deaths but these were not vaccine-related.
The Commission on Appointments rejected Ubial's nomination.
This was the same vaccine used by the Department of Heath (DOH) in its school-based immunization program in the National Capital Region, Central Luzon, and Calabarzon. Duque initially said only 733,713 children received doses of Dengvaxia.
The Philippine health chief said on Friday that the government will demand the refund of over 69 million USA dollars it has paid French pharmaceutical company Sanofi Pasteur for the controversial dengue vaccine Dengvaxia.